MBX BIOSCIENCES INC (MBX) Stock Price, Quote, News and Overview
NASDAQ:MBX - Nasdaq - US55287L1017 - Common Stock - Currency: USD
MBX Quote, Performance and Key Statistics
11.13
-0.54 (-4.63%)
The current stock price of MBX is 11.13 USD. In the past month the price decreased by -10.24%.
MBX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 46.57 | 607.37B | ||
| JNJ | JOHNSON & JOHNSON | 17.15 | 413.10B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 16.8 | 231.20B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.1 | 224.40B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 12.41 | 216.66B | ||
| MRK | MERCK & CO. INC. | 10.44 | 201.81B | ||
| PFE | PFIZER INC | 7.15 | 137.76B | ||
| SNY | SANOFI-ADR | 10.78 | 115.68B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.74 | 92.31B | ||
| GSK | GSK PLC-SPON ADR | 8.39 | 75.83B | ||
| ZTS | ZOETIS INC | 23.83 | 66.00B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 47.87 | 45.35B |
Related stock screener links
About MBX
Company Profile
MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of peptide therapies for the treatment of endocrine and metabolic disorders. The company is headquartered in Carmel, Indiana and currently employs 43 full-time employees. The company went IPO on 2024-09-13. The firm is focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company has built its proprietary Precision Endocrine Peptide platform to develop precision peptide therapies that are designed to overcome key limitations of current peptide therapies. Its product candidates and programs include MBX 2109, MBX 1416 and Obesity portfolio. MBX 2109 is a parathyroid hormone peptide prodrug that is designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. MBX 1416 is designed to be a long-acting glucagon-like peptide-1 (GLP-1), receptor antagonist, as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. MBX 4291 is designed to be a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide, receptor co-agonist prodrug.
Company Info
MBX BIOSCIENCES INC
11711 N. Meridian Street, Suite 300
Carmel INDIANA US
Employees: 43
Phone: 13179893100
MBX BIOSCIENCES INC / MBX FAQ
What is the stock price of MBX BIOSCIENCES INC today?
The current stock price of MBX is 11.13 USD. The price decreased by -4.63% in the last trading session.
What is the ticker symbol for MBX BIOSCIENCES INC stock?
The exchange symbol of MBX BIOSCIENCES INC is MBX and it is listed on the Nasdaq exchange.
On which exchange is MBX stock listed?
MBX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for MBX BIOSCIENCES INC stock?
9 analysts have analysed MBX and the average price target is 38.25 USD. This implies a price increase of 243.67% is expected in the next year compared to the current price of 11.13. Check the MBX BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is MBX BIOSCIENCES INC worth?
MBX BIOSCIENCES INC (MBX) has a market capitalization of 371.96M USD. This makes MBX a Small Cap stock.
How many employees does MBX BIOSCIENCES INC have?
MBX BIOSCIENCES INC (MBX) currently has 43 employees.
What are the support and resistance levels for MBX BIOSCIENCES INC (MBX) stock?
MBX BIOSCIENCES INC (MBX) has a support level at 9.73 and a resistance level at 15.22. Check the full technical report for a detailed analysis of MBX support and resistance levels.
Should I buy MBX BIOSCIENCES INC (MBX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of MBX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of MBX, evaluating the profitability, health, valuation and growth aspects
- MBX BIOSCIENCES INC (MBX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- MBX BIOSCIENCES INC (MBX) Sales and EPS estimates to see what analysts future expectations are.
- MBX BIOSCIENCES INC (MBX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- MBX BIOSCIENCES INC (MBX) Insider and Institutional Ownership to learn about the owners and their transactions.
- MBX BIOSCIENCES INC (MBX) Stock Chart to make your own analysis
- MBX BIOSCIENCES INC (MBX) Latest news and press-releases to stay up to date.
Does MBX BIOSCIENCES INC (MBX) stock pay dividends?
MBX does not pay a dividend.
What is the Price/Earnings (PE) ratio of MBX BIOSCIENCES INC (MBX)?
MBX BIOSCIENCES INC (MBX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.22).
What is the Short Interest ratio of MBX BIOSCIENCES INC (MBX) stock?
The outstanding short interest for MBX BIOSCIENCES INC (MBX) is 21.36% of its float. Check the ownership tab for more information on the MBX short interest.
MBX Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to MBX.
MBX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MBX. MBX has a great financial health rating, but its profitability evaluates not so good.
MBX Financial Highlights
Over the last trailing twelve months MBX reported a non-GAAP Earnings per Share(EPS) of -3.22. The EPS decreased by -470.4% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -29.87% | ||
| ROE | -31.21% | ||
| Debt/Equity | 0 |
MBX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 87% to MBX. The Buy consensus is the average rating of analysts ratings from 9 analysts.